====== 11C methionine positron emission tomography ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1dSaW42H3lP17Le-C5oMs82ybOfUrUpXnSZaPGKq4lmqYHMsDN/?limit=15&utm_campaign=pubmed-2&fc=20240509025709}}

{{ ::11c_methionine.png?400|}}
Tumor to normal tissue ratio (T/N ratio) on [[11C]]-[[methionine]] (11C-MET) [[positron emission tomography]]/computed tomography (PET/CT) is affected by variable factors.

===== Indications =====


===== Glioma =====

[[11C methionine positron emission tomography for glioma]].

====Recurrent brain tumors ====
The visual assessment showed no significant difference from quantitative assessment of MET-PET with a relevant cut-off value for the differentiation of recurrent brain tumors from radiation-induced necrosis
((Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, Matsunaga S,
Shuto T, Akabane A, Miyata Y, Sakai S, Kubota K. Differentiation of Brain Tumor
Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual
Assessment versus Quantitative Assessment. PLoS One. 2015 Jul 13;10(7):e0132515. 
doi: 10.1371/journal.pone.0132515. eCollection 2015. PubMed PMID: 26167681;
PubMed Central PMCID: PMC4500444.
)).

===== Meningioma =====

see [[11C methionine positron emission tomography for meningioma]].

====Acromegaly====
MET-PET is a sensitive technique for diagnosing persistent [[acromegaly]] and its coregistration with 3T MRI has demonstrated a better definition of the interface, extension and location of the lesion in the management of active postoperative acromegaly
((Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J,
Romero-Moreno L, Arraez-Sanchez M. Clinical Usefulness of Coregistered
11C-Methionine Pet/ 3t Mri at the Follow Up of Acromegaly. World Neurosurg. 2013 
Nov 13. pii: S1878-8750(13)01431-9. doi: 10.1016/j.wneu.2013.11.011. [Epub ahead 
of print] PubMed PMID: 24239736.
)).